Recent Posts
- AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
- AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
- AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Recent Comments
No comments to show.